Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 INDUSTRY INSIGHTS
5 EPIDERMIOLOGY
6 REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION
7.1.2 INCREASING EARLY DIAGNOSIS OF LUNGS CANCER
7.1.3 INCREASING CASES OF LUNG CANCER
7.1.4 RISE IN PRODUCT APPROVALS
7.2 RESTRAINTS
7.2.1 POOR & LATE DIAGNOSIS OF LUNG CANCER
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY
7.3 OPPORTUNITIES
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS
7.3.3 RISING AWARENESS OF LUNG CANCER
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS
7.4.2 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
7.4.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
8 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 IMAGING INSTRUMENTS
8.2.1.1 CT SYSTEMS
8.2.1.2 ULTRASOUND SYSTEMS
8.2.1.3 MRI SYSTEMS
8.2.1.4 OTHERS
8.2.2 BIOPSY INSTRUMENTS
8.2.2.1 NEEDLE BIOPSY
8.2.2.2 ENDOSCOPIC BIOPSY
8.2.2.3 CORE BIOPSY
8.2.2.4 OTHERS
8.2.3 PATHOLOGY-BASED INSTRUMENTS
8.2.3.1 SLIDE STAINING SYSTEMS
8.2.3.2 TISSUE PROCESSING SYSTEMS
8.2.3.3 CELL PROCESSORS
8.2.3.4 PCR INSTRUMENTS
8.2.3.5 OTHERS PATHOLOGY-BASED INSTRUMENTS
8.3 CONSUMABLES AND ACCESSORIES
8.3.1 KITS
8.3.1.1 DNA POLYMERASE KITS
8.3.1.2 NUCLEIC ACID ISOLATION KITS
8.3.1.3 PCR KITS
8.3.1.4 OTHERS
8.3.2 REAGENTS
8.3.2.1 ASSAYS
8.3.2.2 BUFFERS
8.3.2.3 PRIMERS
8.3.2.4 OTHERS
8.3.3 PROBES
8.3.4 OTHER CONSUMABLES
9 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN
9.2.2 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
9.2.3 CHEST X-RAY
9.2.4 BONE SCAN
9.2.5 MRI
9.2.6 OTHERS
9.3 BIOMARKERS TEST
9.3.1 EGFR MUTATION TEST
9.3.2 KRAS MUTATION TEST
9.3.3 ALK TEST
9.3.4 HER2 TEST
9.3.5 OTHERS
9.4 BIOPSY
9.4.1 NEEDLE BIOPSY
9.4.2 BRONCHOSCOPY BIOPSY
9.4.3 CORE BIOPSY
9.4.4 OTHERS
9.5 BLOOD TEST
9.5.1 COMPLETE BLOOD COUNT (CBC)
9.5.2 BLOOD CHEMISTRY TESTS
9.5.3 OTHERS
9.6 OTHERS
10 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 NON-SMALL CELL LUNG CANCER
10.3 SMALL CELL LUNG CANCER
11 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITAL
11.3 ASSOCIATED LABS
11.4 INDEPENDENT DIAGNOSTIC LABORATORIES
11.5 DIAGNOSTIC IMAGING CENTERS
11.6 CANCER RESEARCH INSTITUTES
11.7 OTHERS
12 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
13 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 F. HOFFMANN-LA ROCHE LTD. (2022)
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 THERMO FISHER SCIENTIFIC INC. (2022)
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 ABBOTT (2022)
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 QUEST DIAGNOSTICS INCORPORATED (2022)
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 BIODESIX (2022)
16.5.1 COMPANY PROFILE
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENTS
16.6 AMOY DIAGNOSTICS CO., LTD. (2022)
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 BIO-RAD LABORATORIES, INC. (2022)
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENTS
16.8 BIOCARTIS (2022)
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 BODITECH MED INC.
16.9.1 COMPANY PROFILE
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENTS
16.1 DANAHER (2022)
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENTS
16.11 DIASORIN S.P.A. (2022)
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 EXACT SCIENCES UK, LTD. (SUBSIDIARY OF EXACT SCIENCE CORPORATION) (2022)
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 20/20 GENE SYSTEMS
16.13.1 COMPANY PROFILE
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 GUARDANT HEALTH INC.
16.14.1 COMPANY PROFILE
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 INIVATA LTD.
16.15.1 COMPANY PROFILE
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
16.16 LALPATHLABS.COM (2022)
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENTS
16.17 LUNGLIFE AI, INC. (2022)
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 MEDGENOME
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENTS
16.19 MYRIAD GENETICS, INC.
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENTS
16.2 NEOGENOMICS LABORATORIES (2022)
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENTS
16.21 NANOSTRING (2022)
16.21.1 COMPANY SNAPSHOT
16.21.2 REVENUE ANALYSIS
16.21.3 PRODUCT PORTFOLIO
16.21.4 RECENT DEVELOPMENTS
16.22 NANOENTEK
16.22.1 COMPANY PROFILE
16.22.2 PRODUCT PORTFOLIO
16.22.3 RECENT DEVELOPMENTS
16.23 ONCOCYTE CORPORATION
16.23.1 COMPANY PROFILE
16.23.2 SERVICE PORTFOLIO
16.23.3 RECENT DEVELOPMENTS
16.24 PERKINELMER INC
16.24.1 COMPANY PROFILE
16.24.2 REVENUE ANALYSIS
16.24.3 PRODUCT PORTFOLIO
16.24.4 RECENT DEVELOPMENTS
16.25 PLEXBIO
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENTS
16.26 QIAGEN
16.26.1 COMPANY SNAPSHOT
16.26.2 REVENUE ANALYSIS
16.26.3 PRODUCT PORTFOLIO
16.26.4 RECENT DEVELOPMENTS
16.27 SIEMENS HEALTHCARE GMBH
16.27.1 COMPANY SNAPSHOT
16.27.2 REVENUE ANALYSIS
16.27.3 PRODUCT PORTFOLIO
16.27.4 RECENT DEVELOPMENTS
16.28 VERACYTE, INC. (2022)
16.28.1 COMPANY SNAPSHOT
16.28.2 REVENUE ANALYSIS
16.28.3 PRODUCT PORTFOLIO
16.28.4 RECENT DEVELOPMENTS
16.29 VELA DIAGNOSTICS
16.29.1 COMPANY PROFILE
16.29.2 PRODUCT PORTFOLIO
16.29.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 DIFFERENT TYPES OF CANCER SCREENING TESTS FOR DIFFERENT TYPES OF CANCERS
TABLE 2 LUNG CANCER RATES
TABLE 3 APPROVED DIAGNOSTICS OF LUNGS CANCER
TABLE 4 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA CONSUMABLES & ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA OTHERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA SMALL CELL LUNG CANCER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA HOSPITAL IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA ASSOCIATED LABS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA INDEPENDENT DIAGNOSTIC LABORATORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA DIAGNOSTIC IMAGING CENTERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA CANCER RESEARCH INSTITUTES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA OTHERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA DIRECT TENDER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA RETAIL SALES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 53 U.S. LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 U.S. INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 U.S. PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 U.S. IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 U.S. BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 U.S. CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 59 U.S. KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 60 U.S. REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 U.S. LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 62 U.S. BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 U.S. IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 64 U.S. BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 65 U.S. BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 66 U.S. LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 67 U.S. LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 68 U.S. LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 69 CANADA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 70 CANADA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 CANADA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 CANADA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 CANADA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 74 CANADA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 CANADA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 76 CANADA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 CANADA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 78 CANADA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 79 CANADA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 80 CANADA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 81 CANADA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 82 CANADA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 83 CANADA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 84 CANADA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 85 MEXICO LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 86 MEXICO INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 87 MEXICO PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 88 MEXICO IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 89 MEXICO BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 MEXICO CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 91 MEXICO KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 92 MEXICO REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 93 MEXICO LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 94 MEXICO BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 95 MEXICO IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 96 MEXICO BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 97 MEXICO BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 98 MEXICO LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 99 MEXICO LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 100 MEXICO LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA LUNGS CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA LUNG CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT LUNG CANCER IS EXPECTED TO DRIVE THE NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET
FIGURE 14 THE NORTH AMERICA MORTALITY RATE DUE TO CANCER
FIGURE 15 THE DATA GIVEN BELOW SHOWS THE INCREASING NORTH AMERICA CANCER RATE IN 2020
FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT
FIGURE 17 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 18 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 19 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 20 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 22 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 23 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 24 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 25 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 26 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 27 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 28 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 29 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 30 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 31 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 32 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 33 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 34 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 35 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 36 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 37 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 38 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 39 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 40 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 41 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 42 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
